PureTech Health (PRTC) Share Price, News & Analysis

Company Overview

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: 115 to 118.20
• 50-Day Range: 115.20 to 146.60
• 52-Week Range: 100.40 to 178
• Volume: 576,456 shs
• Average Volume: 681,593 shs
• Market Capitalization: £280.89 million
• P/E Ratio: 684.71
• Dividend Yield: N/A
• Price Target: GBX 455
• Consensus Rating: Buy

PureTech Health Stock Analysis - MarketRank™

PureTech Health scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

PureTech Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

PureTech Health has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of PureTech Health is 684.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 262.22.

Price to Earnings Ratio vs. Sector

The P/E ratio of PureTech Health is 684.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 59.11.

Price to Book Value per Share Ratio

PureTech Health has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PRTC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PureTech Health does not currently pay a dividend.

Dividend Growth

PureTech Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for PRTC.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for PureTech Health this week, compared to 1 article on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, PureTech Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought £1,677.39 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

13.13% of the stock of PureTech Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

53.06% of the stock of PureTech Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRTC Stock Analysis - Frequently Asked Questions

How have PRTC shares performed this year?

PureTech Health's stock was trading at GBX 150.20 at the start of the year. Since then, PRTC shares have decreased by 22.5% and is now trading at GBX 116.40.

How do I buy shares of PureTech Health?

Shares of PRTC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of PureTech Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PureTech Health investors own include IQE (IQE), Royal Dutch Shell (RDSB), BP (BP), GSK (GSK), Hummingbird Resources (HUM), Plug Power (PLUG) and AstraZeneca (AZN).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:PRTC
• CIK: N/A
• Web: puretechhealth.com
• Phone: +1-617-4822333
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for PureTech Health: GBX 455
• High Price Target: GBX 455
• Low Price Target: GBX 455
• Potential Upside/Downside: +290.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 0.17
• Trailing P/E Ratio: 684.71
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£91.86 million
• Net Margins: -17,620.94%
• Pretax Margin: N/A
• Return on Equity: -21.15%
• Return on Assets: -13.39%

Debt

• Debt-to-Equity Ratio: 45.82
• Current Ratio: 3.68
• Quick Ratio: 2.51

Sales & Book Value

• Annual Sales: £6.17 million
• Price / Sales: 45.55
• Cash Flow: GBX 54.35 per share
• Price / Cash Flow: 2.14
• Book Value: GBX 113.55 per share
• Price / Book: 1.03

Miscellaneous

• Outstanding Shares: 241,316,000
• Free Float: N/A
• Market Cap: £280.89 million
• Optionable: Not Optionable
• Beta: 1.02